BOSTON and LONDON, Jan. 28, 2025 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company that aims to discover and develop transformational medicines for patients, today announced that members of its management team will participate in the following investor conferences:
Event: Guggenheim SMID Cap Biotech Conference
Date: February 6, 2025
Fireside Chat: 1:00 PM ET
Event: Oppenheimer 35th Annual Healthcare Life Sciences Conference
Date: February 12, 2025
Fireside Chat: 10:40 AM ET
Event: TD Cowen 45th Annual Health Care Conference
Date: March 4, 2025
Fireside Chat: 1:50 PM ET
Event: Leerink Partners Global Healthcare Conference
Date: March 11, 2025
Fireside Chat: 10:00 AM ET
Access to the live webcasts of these events, as well as archived recordings, will be available under the “Events and Publications” tab on the investor relations section of the Centessa Pharmaceuticals website at https://investors.centessa.com/.
About Centessa Pharmaceuticals
Centessa Pharmaceuticals plc is a clinical-stage pharmaceutical company that aims to discover and develop medicines that are transformational for patients. We are developing potential best-in-class orexin receptor 2 (OX2R) agonists intended to be orally administered for the treatment of sleep-wake disorders including narcolepsy type 1 (NT1), narcolepsy type 2 (NT2) and idiopathic hypersomnia (IH), and excessive daytime sleepiness (EDS) in neurological, neurodegenerative, and psychiatric conditions. We also anticipate that our OX2R agonists may have utility in treating impaired attention, cognitive deficits, fatigue, and other symptoms. Our earlier stage pipeline is focused on immuno-oncology with our proprietary LockBody technology platform.
Contact:
Kristen K. Sheppard, Esq.
SVP of Investor Relations
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$11.28 |
| Daily Change: | -0.40 -3.42 |
| Daily Volume: | 1,446,824 |
| Market Cap: | US$1.490B |
March 24, 2025 November 12, 2024 September 11, 2024 | |
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORE
ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...
CLICK TO LEARN MORE
